Please login to the form below

Not currently logged in
Email:
Password:

Breast cancer drug shows improved survival

Eisai's eribulin shown to improve overall survival in heavily pre-treated patients compared to treatment of physician's choice, according to study

Eribulin mesylate (E7389), Eisai's treatment for heavily pre-treated metastatic breast cancer patients, has been shown to improve median overall survival (OS) significantly compared with Treatment of Physician's Choice (TPC), according to results of a phase III study presented at the American Society of Clinical Oncology (ASCO) annual meeting.

Eribulin, a synthetic analogue of halichondrin B (derived from a marine sponge), is a non-taxane, microtubule dynamics inhibitor.

The open-label, randomised, multicentre EMBRACE study was designed to compare overall survival in patients treated with eribulin versus a TPC arm. The study enrolled 762 patients with locally recurrent or metastatic breast cancer who were previously treated with between two and five prior chemotherapies. Patients were randomised 2:1 to receive either eribulin or TPC.

Patients who received eribulin had a median overall survival of 13.12 months, compared with 10.65 months for TPC. This represents an improvement in median overall survival of 2.5 months for patients treated with eribulin compared with TPC. Treatment-emergent serious adverse events were reported in 25 per cent of patients in the eribulin arm and 25.9 per cent of patients in the TPC.

EMBRACE is the first single-agent phase III trial to demonstrate improved survival against a variety of other agents in this patient population. In March, Eisai submitted applications for eribulin in the treatment of locally advanced or metastatic breast cancer to regulatory authorities in the EU, Japan and the US.

7th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics